NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
Lui Shiong LeeAdelene Y L SimChee Wee OngXinyan YangCedric C Y NgWei LiuVikneswari RajasegaranAbner M S LimEdwin Jonathan AslimNye Thane NgoLi-Yan KhorRavindran KanesvaranJohn Carson Jr AllenKae Jack TayJohn Shyi Peng YuenTsung Wen ChongSun Sien Henry HoBin Tean TehMatthew Chin Heng ChuaPublished in: Prostate cancer and prostatic diseases (2022)
A 12-week course of neoadjuvant apalutamide prior to RP did not meet the primary endpoint of pCR in this trial. Tumours with low androgen receptor activity or of the PAM50 basal subtype may have a reduced response to apalutamide.